These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 35792541)

  • 1. The Impact of Temporal Variation in ICG Administration on Axillary Node Identification During Reverse Mapping Procedures.
    Roman MM; Nogaret JM; Veys I; Delrue P; Eddy C; Karler C; Marmol VD; Bourgeois P
    Chirurgia (Bucur); 2022 Jun; 117(3):305-311. PubMed ID: 35792541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indo-cyanine green administration to identify loss of lymph after axillary lymph node dissection.
    Roman MM; Delrue P; Karler C; Del Marmol V; Bourgeois P
    Front Oncol; 2023; 13():1045495. PubMed ID: 36994214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analyzing non-sentinel axillary metastases in patients with T3-T4 cN0 early breast cancer and tumor-involved sentinel lymph nodes undergoing breast-conserving therapy or mastectomy.
    Riedel F; Heil J; Feisst M; Moderow M; von Au A; Domschke C; Michel L; Schaefgen B; Golatta M; Hennigs A
    Breast Cancer Res Treat; 2020 Nov; 184(2):627-636. PubMed ID: 32816190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Axillary reverse mapping with indocyanine green or isosulfan blue demonstrate similar crossover rates to radiotracer identified sentinel nodes.
    Foster D; Choy N; Porter C; Ahmed S; Wapnir I
    J Surg Oncol; 2018 Mar; 117(3):336-340. PubMed ID: 29228459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does the result of completion axillary lymph node dissection influence the recommendation for adjuvant treatment in sentinel lymph node-positive patients?
    Sávolt A; Polgár C; Musonda P; Mátrai Z; Rényi-Vámos F; Tóth L; Kásler M; Péley G
    Clin Breast Cancer; 2013 Oct; 13(5):364-70. PubMed ID: 23773380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contemporary Axillary Management in cT1-2N0 Breast Cancer with One or Two Positive Sentinel Lymph Nodes: Factors Associated with Completion Axillary Lymph Node Dissection Within the National Cancer Database.
    Stafford AP; Hoskin TL; Day CN; Sanders SB; Boughey JC
    Ann Surg Oncol; 2022 Aug; 29(8):4740-4749. PubMed ID: 35451727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subsequent axillary surgery after sentinel lymph node biopsy: results from the BreastSurgANZ Quality Audit 2006-2010.
    Chong C; Walters D; de Silva P; Taylor C; Spillane A; Kollias J; Pyke C; Campbell I; Maddern G
    Breast; 2013 Dec; 22(6):1215-9. PubMed ID: 24157405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Locoregional Management of the Axilla in Mastectomy Patients with One or Two Positive Sentinel Nodes: The Role of Intraoperative Pathology.
    Davis J; Boughey JC; Hoskin TL; Day CN; Cheville JC; Piltin MA; Hieken TJ
    Clin Breast Cancer; 2021 Oct; 21(5):458-465. PubMed ID: 33839043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution of the Use of Completion Axillary Lymph Node Dissection in Patients with T1/2N0M0 Breast Cancer and Tumour-Involved Sentinel Lymph Nodes Undergoing Mastectomy: A Cohort Study.
    Hennigs A; Riedel F; Feißt M; Köpke M; Rezai M; Nitz U; Moderow M; Golatta M; Sohn C; Heil J
    Ann Surg Oncol; 2019 Aug; 26(8):2435-2443. PubMed ID: 31049766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical relevance of axillary reverse mapping (ARM): study protocol for a randomized controlled trial.
    Klompenhouwer EG; Gobardhan PD; Beek MA; Voogd AC; Luiten EJ
    Trials; 2013 Apr; 14():111. PubMed ID: 23782712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A positive intramammary lymph node does not mandate a complete axillary node dissection.
    Diaz R; Degnim AC; Boughey JC; Nassar A; Jakub JW
    Am J Surg; 2012 Feb; 203(2):151-5. PubMed ID: 21788008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Women Could Avoid Axillary Lymph Node Dissection by Choosing Breast-Conserving Therapy Instead of Mastectomy.
    Vane MLG; Hunter-Squires J; Kim S; Smidt ML; Giuliano AE
    Ann Surg Oncol; 2021 May; 28(5):2522-2528. PubMed ID: 33586070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial.
    Sávolt Á; Péley G; Polgár C; Udvarhelyi N; Rubovszky G; Kovács E; Győrffy B; Kásler M; Mátrai Z
    Eur J Surg Oncol; 2017 Apr; 43(4):672-679. PubMed ID: 28139362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of completion axillary lymph node dissection in patients with positive sentinel lymph nodes.
    Karam AK; Hsu M; Patil S; Stempel M; Traina TA; Ho AY; Cody HS; Port ER; Morrow M; Gemignani ML
    Ann Surg Oncol; 2009 Jul; 16(7):1952-8. PubMed ID: 19381724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can axillary reverse mapping avoid lymphedema in node positive breast cancer patients?
    Tausch C; Baege A; Dietrich D; Vergin I; Heuer H; Heusler RH; Rageth C
    Eur J Surg Oncol; 2013 Aug; 39(8):880-6. PubMed ID: 23735162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The involvement of axillary reverse mapping nodes in patients with clinically node-negative breast cancer.
    Noguchi M; Inokuchi M; Yokoi-Noguchi M; Morioka E
    Breast Cancer; 2022 Mar; 29(2):209-215. PubMed ID: 34591289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility study of axillary reverse mapping for patients with clinically node-negative breast cancer.
    Noguchi M; Noguchi M; Ohno Y; Morioka E; Nakano Y; Kosaka T; Kurose N; Minato H
    Eur J Surg Oncol; 2016 May; 42(5):650-6. PubMed ID: 27005806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Population-Based Study of the Effects of a Regional Guideline for Completion Axillary Lymph Node Dissection on Axillary Surgery in Patients with Breast Cancer.
    Tsao MW; Cornacchi SD; Hodgson N; Simunovic M; Thabane L; Cheng J; O'Brien MA; Strang B; Mukherjee SD; Lovrics PJ
    Ann Surg Oncol; 2016 Oct; 23(10):3354-64. PubMed ID: 27342830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is axillary reverse mapping feasible in breast cancer patients?
    Noguchi M; Miura S; Morioka E; Ohno Y; Yokoi-Noguchi M; Nakano Y; Kosaka T
    Eur J Surg Oncol; 2015 Apr; 41(4):442-9. PubMed ID: 25704555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Axillary lymph node recurrence after sentinel lymph node biopsy performed using a combination of indocyanine green fluorescence and the blue dye method in early breast cancer.
    Inoue T; Nishi T; Nakano Y; Nishimae A; Sawai Y; Yamasaki M; Inaji H
    Breast Cancer; 2016 Mar; 23(2):295-300. PubMed ID: 25348937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.